Differentiation of the drug‐binding sites of calmodulin

Calmodulin contains several binding sites for hydrophobic compounds. The apparent specificity of various ‘calmodulin antagonists’ for these sites was investigated. The Ki values for the inhibition of calmodulin‐activated cyclic‐nucleotide phosphodiesterase and myosin light‐chain kinase was determine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of biochemistry 1987-04, Vol.164 (2), p.411-420
Hauptverfasser: ZIMMER, Manfred, HOFMANN, Franz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 420
container_issue 2
container_start_page 411
container_title European journal of biochemistry
container_volume 164
creator ZIMMER, Manfred
HOFMANN, Franz
description Calmodulin contains several binding sites for hydrophobic compounds. The apparent specificity of various ‘calmodulin antagonists’ for these sites was investigated. The Ki values for the inhibition of calmodulin‐activated cyclic‐nucleotide phosphodiesterase and myosin light‐chain kinase was determined. In addition, the Kd values of the same compounds for binding to calmodulin were measured. The compounds could be separated into four groups. Group I and II compounds inhibited competitively the activation of the phosphodiesterase and myosin light‐chain kinase by calmodulin. Group I compounds inhibited the activation of the phosphodiesterase and myosin light‐chain kinase at identical concentrations. In contrast, group II compounds inhibited the activation of the phosphodiesterase at 5–10‐fold lower concentrations than that of myosin light‐chain kinase. Group III compounds inhibited the activation of these enzymes by an uncompetitive mechanism. Group IV compounds inhibited the activation of the phosphodiesterase with Ki values above 10 μM and did not affect the activation of myosin light‐chain kinase. Binding of [3H]bepridil to calmodulin under equilibrium conditions yielded one high‐affinity site (apparent Kd 0.4 μM) and four low affinity sites (apparent Kd 44 μM). Group I compounds interfered with the binding of bepridil to the high and low‐affinity sites in a competitive manner. Group II compounds interfered in a noncompetitive manner with the high‐affinity site and apparently competed only with one of the low‐affinity sites. Group III compounds did not compete with any of the bepridil‐binding sites. Nimodipine, a group III compound, bound to one site on calmodulin with a Kd value of 1.1 μM. Other dihydropyridines competed with [3H]nimodipine for this site. The group I and II compounds, trifluoperazine and prenylamine, did not affect the binding of [3H]nimodipine. These data show that ‘calmodulin antagonists’ can be differentiated into at least three distinct groups. Kinetic and binding data suggest that the three groups bind to at least three different sites on calmodulin. Selective occupation of these sites may inhibit specifically the activation of distinct enzymes.
doi_str_mv 10.1111/j.1432-1033.1987.tb11073.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77474474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77474474</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5481-3e1c814e60d6c17701f67846e0cfb8958ce563a80a3c9a19b377faebe326c7403</originalsourceid><addsrcrecordid>eNqVkMtKxDAUhoMoOl4eQSgi7lpzJmnSuhEdHRUGXKjrkKYnmqHTatPizM5H8Bl9ElumzFYMB7L4v3PhI-QEaATdO59HwNk4BMpYBGkioyYDoJJFyy0y2kTbZEQp8HCcxmKP7Hs_p5SKVMhdsssoGwuQI5LeOGuxxrJxunFVGVQ2aN4wyOv29efrO3Nl7srXwLsGfZ8ZXSyqvC1ceUh2rC48Hg3_AXmZ3j5P7sPZ493D5GoWmpgnEDIEkwBHQXNhQEoKVsiEC6TGZkkaJwZjwXRCNTOphjRjUlqNGXYHGskpOyBn67nvdfXRom_UwnmDRaFLrFqvpOSSd_UnCFymIhFxB16sQVNX3tdo1XvtFrpeKaCqF6zmqreoeouqF6wGwWrZNR8PW9psgfmmdTDa5adDrn0ny9a6NM5vMBkLygR02OUa-3QFrv5xgJreXj9xAPYL8WWXgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14796865</pqid></control><display><type>article</type><title>Differentiation of the drug‐binding sites of calmodulin</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>ZIMMER, Manfred ; HOFMANN, Franz</creator><creatorcontrib>ZIMMER, Manfred ; HOFMANN, Franz</creatorcontrib><description>Calmodulin contains several binding sites for hydrophobic compounds. The apparent specificity of various ‘calmodulin antagonists’ for these sites was investigated. The Ki values for the inhibition of calmodulin‐activated cyclic‐nucleotide phosphodiesterase and myosin light‐chain kinase was determined. In addition, the Kd values of the same compounds for binding to calmodulin were measured. The compounds could be separated into four groups. Group I and II compounds inhibited competitively the activation of the phosphodiesterase and myosin light‐chain kinase by calmodulin. Group I compounds inhibited the activation of the phosphodiesterase and myosin light‐chain kinase at identical concentrations. In contrast, group II compounds inhibited the activation of the phosphodiesterase at 5–10‐fold lower concentrations than that of myosin light‐chain kinase. Group III compounds inhibited the activation of these enzymes by an uncompetitive mechanism. Group IV compounds inhibited the activation of the phosphodiesterase with Ki values above 10 μM and did not affect the activation of myosin light‐chain kinase. Binding of [3H]bepridil to calmodulin under equilibrium conditions yielded one high‐affinity site (apparent Kd 0.4 μM) and four low affinity sites (apparent Kd 44 μM). Group I compounds interfered with the binding of bepridil to the high and low‐affinity sites in a competitive manner. Group II compounds interfered in a noncompetitive manner with the high‐affinity site and apparently competed only with one of the low‐affinity sites. Group III compounds did not compete with any of the bepridil‐binding sites. Nimodipine, a group III compound, bound to one site on calmodulin with a Kd value of 1.1 μM. Other dihydropyridines competed with [3H]nimodipine for this site. The group I and II compounds, trifluoperazine and prenylamine, did not affect the binding of [3H]nimodipine. These data show that ‘calmodulin antagonists’ can be differentiated into at least three distinct groups. Kinetic and binding data suggest that the three groups bind to at least three different sites on calmodulin. Selective occupation of these sites may inhibit specifically the activation of distinct enzymes.</description><identifier>ISSN: 0014-2956</identifier><identifier>EISSN: 1432-1033</identifier><identifier>DOI: 10.1111/j.1432-1033.1987.tb11073.x</identifier><identifier>PMID: 3032617</identifier><identifier>CODEN: EJBCAI</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>2',3'-Cyclic-Nucleotide Phosphodiesterases - antagonists &amp; inhibitors ; Animals ; Applied sciences ; Bepridil ; Binding Sites ; calmodulin ; Calmodulin - antagonists &amp; inhibitors ; Calmodulin - metabolism ; drugs ; Exact sciences and technology ; In Vitro Techniques ; Kinetics ; Myosin-Light-Chain Kinase - antagonists &amp; inhibitors ; Nimodipine - metabolism ; Other techniques and industries ; Pyrrolidines - metabolism ; Trifluoperazine - metabolism</subject><ispartof>European journal of biochemistry, 1987-04, Vol.164 (2), p.411-420</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5481-3e1c814e60d6c17701f67846e0cfb8958ce563a80a3c9a19b377faebe326c7403</citedby><cites>FETCH-LOGICAL-c5481-3e1c814e60d6c17701f67846e0cfb8958ce563a80a3c9a19b377faebe326c7403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7560361$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3032617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ZIMMER, Manfred</creatorcontrib><creatorcontrib>HOFMANN, Franz</creatorcontrib><title>Differentiation of the drug‐binding sites of calmodulin</title><title>European journal of biochemistry</title><addtitle>Eur J Biochem</addtitle><description>Calmodulin contains several binding sites for hydrophobic compounds. The apparent specificity of various ‘calmodulin antagonists’ for these sites was investigated. The Ki values for the inhibition of calmodulin‐activated cyclic‐nucleotide phosphodiesterase and myosin light‐chain kinase was determined. In addition, the Kd values of the same compounds for binding to calmodulin were measured. The compounds could be separated into four groups. Group I and II compounds inhibited competitively the activation of the phosphodiesterase and myosin light‐chain kinase by calmodulin. Group I compounds inhibited the activation of the phosphodiesterase and myosin light‐chain kinase at identical concentrations. In contrast, group II compounds inhibited the activation of the phosphodiesterase at 5–10‐fold lower concentrations than that of myosin light‐chain kinase. Group III compounds inhibited the activation of these enzymes by an uncompetitive mechanism. Group IV compounds inhibited the activation of the phosphodiesterase with Ki values above 10 μM and did not affect the activation of myosin light‐chain kinase. Binding of [3H]bepridil to calmodulin under equilibrium conditions yielded one high‐affinity site (apparent Kd 0.4 μM) and four low affinity sites (apparent Kd 44 μM). Group I compounds interfered with the binding of bepridil to the high and low‐affinity sites in a competitive manner. Group II compounds interfered in a noncompetitive manner with the high‐affinity site and apparently competed only with one of the low‐affinity sites. Group III compounds did not compete with any of the bepridil‐binding sites. Nimodipine, a group III compound, bound to one site on calmodulin with a Kd value of 1.1 μM. Other dihydropyridines competed with [3H]nimodipine for this site. The group I and II compounds, trifluoperazine and prenylamine, did not affect the binding of [3H]nimodipine. These data show that ‘calmodulin antagonists’ can be differentiated into at least three distinct groups. Kinetic and binding data suggest that the three groups bind to at least three different sites on calmodulin. Selective occupation of these sites may inhibit specifically the activation of distinct enzymes.</description><subject>2',3'-Cyclic-Nucleotide Phosphodiesterases - antagonists &amp; inhibitors</subject><subject>Animals</subject><subject>Applied sciences</subject><subject>Bepridil</subject><subject>Binding Sites</subject><subject>calmodulin</subject><subject>Calmodulin - antagonists &amp; inhibitors</subject><subject>Calmodulin - metabolism</subject><subject>drugs</subject><subject>Exact sciences and technology</subject><subject>In Vitro Techniques</subject><subject>Kinetics</subject><subject>Myosin-Light-Chain Kinase - antagonists &amp; inhibitors</subject><subject>Nimodipine - metabolism</subject><subject>Other techniques and industries</subject><subject>Pyrrolidines - metabolism</subject><subject>Trifluoperazine - metabolism</subject><issn>0014-2956</issn><issn>1432-1033</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkMtKxDAUhoMoOl4eQSgi7lpzJmnSuhEdHRUGXKjrkKYnmqHTatPizM5H8Bl9ElumzFYMB7L4v3PhI-QEaATdO59HwNk4BMpYBGkioyYDoJJFyy0y2kTbZEQp8HCcxmKP7Hs_p5SKVMhdsssoGwuQI5LeOGuxxrJxunFVGVQ2aN4wyOv29efrO3Nl7srXwLsGfZ8ZXSyqvC1ceUh2rC48Hg3_AXmZ3j5P7sPZ493D5GoWmpgnEDIEkwBHQXNhQEoKVsiEC6TGZkkaJwZjwXRCNTOphjRjUlqNGXYHGskpOyBn67nvdfXRom_UwnmDRaFLrFqvpOSSd_UnCFymIhFxB16sQVNX3tdo1XvtFrpeKaCqF6zmqreoeouqF6wGwWrZNR8PW9psgfmmdTDa5adDrn0ny9a6NM5vMBkLygR02OUa-3QFrv5xgJreXj9xAPYL8WWXgA</recordid><startdate>19870415</startdate><enddate>19870415</enddate><creator>ZIMMER, Manfred</creator><creator>HOFMANN, Franz</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19870415</creationdate><title>Differentiation of the drug‐binding sites of calmodulin</title><author>ZIMMER, Manfred ; HOFMANN, Franz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5481-3e1c814e60d6c17701f67846e0cfb8958ce563a80a3c9a19b377faebe326c7403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>2',3'-Cyclic-Nucleotide Phosphodiesterases - antagonists &amp; inhibitors</topic><topic>Animals</topic><topic>Applied sciences</topic><topic>Bepridil</topic><topic>Binding Sites</topic><topic>calmodulin</topic><topic>Calmodulin - antagonists &amp; inhibitors</topic><topic>Calmodulin - metabolism</topic><topic>drugs</topic><topic>Exact sciences and technology</topic><topic>In Vitro Techniques</topic><topic>Kinetics</topic><topic>Myosin-Light-Chain Kinase - antagonists &amp; inhibitors</topic><topic>Nimodipine - metabolism</topic><topic>Other techniques and industries</topic><topic>Pyrrolidines - metabolism</topic><topic>Trifluoperazine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ZIMMER, Manfred</creatorcontrib><creatorcontrib>HOFMANN, Franz</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ZIMMER, Manfred</au><au>HOFMANN, Franz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differentiation of the drug‐binding sites of calmodulin</atitle><jtitle>European journal of biochemistry</jtitle><addtitle>Eur J Biochem</addtitle><date>1987-04-15</date><risdate>1987</risdate><volume>164</volume><issue>2</issue><spage>411</spage><epage>420</epage><pages>411-420</pages><issn>0014-2956</issn><eissn>1432-1033</eissn><coden>EJBCAI</coden><abstract>Calmodulin contains several binding sites for hydrophobic compounds. The apparent specificity of various ‘calmodulin antagonists’ for these sites was investigated. The Ki values for the inhibition of calmodulin‐activated cyclic‐nucleotide phosphodiesterase and myosin light‐chain kinase was determined. In addition, the Kd values of the same compounds for binding to calmodulin were measured. The compounds could be separated into four groups. Group I and II compounds inhibited competitively the activation of the phosphodiesterase and myosin light‐chain kinase by calmodulin. Group I compounds inhibited the activation of the phosphodiesterase and myosin light‐chain kinase at identical concentrations. In contrast, group II compounds inhibited the activation of the phosphodiesterase at 5–10‐fold lower concentrations than that of myosin light‐chain kinase. Group III compounds inhibited the activation of these enzymes by an uncompetitive mechanism. Group IV compounds inhibited the activation of the phosphodiesterase with Ki values above 10 μM and did not affect the activation of myosin light‐chain kinase. Binding of [3H]bepridil to calmodulin under equilibrium conditions yielded one high‐affinity site (apparent Kd 0.4 μM) and four low affinity sites (apparent Kd 44 μM). Group I compounds interfered with the binding of bepridil to the high and low‐affinity sites in a competitive manner. Group II compounds interfered in a noncompetitive manner with the high‐affinity site and apparently competed only with one of the low‐affinity sites. Group III compounds did not compete with any of the bepridil‐binding sites. Nimodipine, a group III compound, bound to one site on calmodulin with a Kd value of 1.1 μM. Other dihydropyridines competed with [3H]nimodipine for this site. The group I and II compounds, trifluoperazine and prenylamine, did not affect the binding of [3H]nimodipine. These data show that ‘calmodulin antagonists’ can be differentiated into at least three distinct groups. Kinetic and binding data suggest that the three groups bind to at least three different sites on calmodulin. Selective occupation of these sites may inhibit specifically the activation of distinct enzymes.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>3032617</pmid><doi>10.1111/j.1432-1033.1987.tb11073.x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-2956
ispartof European journal of biochemistry, 1987-04, Vol.164 (2), p.411-420
issn 0014-2956
1432-1033
language eng
recordid cdi_proquest_miscellaneous_77474474
source MEDLINE; Alma/SFX Local Collection
subjects 2',3'-Cyclic-Nucleotide Phosphodiesterases - antagonists & inhibitors
Animals
Applied sciences
Bepridil
Binding Sites
calmodulin
Calmodulin - antagonists & inhibitors
Calmodulin - metabolism
drugs
Exact sciences and technology
In Vitro Techniques
Kinetics
Myosin-Light-Chain Kinase - antagonists & inhibitors
Nimodipine - metabolism
Other techniques and industries
Pyrrolidines - metabolism
Trifluoperazine - metabolism
title Differentiation of the drug‐binding sites of calmodulin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T09%3A31%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differentiation%20of%20the%20drug%E2%80%90binding%20sites%20of%20calmodulin&rft.jtitle=European%20journal%20of%20biochemistry&rft.au=ZIMMER,%20Manfred&rft.date=1987-04-15&rft.volume=164&rft.issue=2&rft.spage=411&rft.epage=420&rft.pages=411-420&rft.issn=0014-2956&rft.eissn=1432-1033&rft.coden=EJBCAI&rft_id=info:doi/10.1111/j.1432-1033.1987.tb11073.x&rft_dat=%3Cproquest_cross%3E77474474%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14796865&rft_id=info:pmid/3032617&rfr_iscdi=true